Supply Chain | April 17, 2026
Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion
The company allocated €56 million to research and development for next-generation line solutions
The company allocated €56 million to research and development for next-generation line solutions
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Discussions will focus on how private space stations can improve access, repeatability and commercial feasibility for advanced biotech experiments
The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities
The CE Mark builds on the company’s ISO 13485 certification, further strengthening confidence in the platform's safety, quality and performance
Subscribe To Our Newsletter & Stay Updated
